StockNews.com Initiates Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)

Analysts at StockNews.com began coverage on shares of Brooklyn ImmunoTherapeutics (NYSE:BTXGet Free Report) in a report issued on Saturday. The brokerage set a “hold” rating on the stock.

Brooklyn ImmunoTherapeutics Stock Performance

Shares of BTX opened at $0.58 on Friday. Brooklyn ImmunoTherapeutics has a one year low of $0.17 and a one year high of $10.10. The stock has a market capitalization of $34.12 million, a price-to-earnings ratio of -0.26 and a beta of 4.61. The stock has a 50 day moving average price of $0.39 and a 200 day moving average price of $1.08.

Brooklyn ImmunoTherapeutics Company Profile

(Get Free Report)

Eterna Therapeutics, Inc is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B.

Recommended Stories

Receive News & Ratings for Brooklyn ImmunoTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brooklyn ImmunoTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.